COSCIENS Biopharma posted $2.7 million in revenue for Q2 2025, with a net loss of $2.4 million driven by integration and restructuring efforts. The company reduced operating expenses by 28% and completed a strategic review of its pipeline while preparing to delist from Nasdaq.